Drug name: Rapamycin + SN38


Related CSCTT Targets

Gastric cancer SP cells [ref.1]

Rapamycin

Cas.no PubChem ID
53123-88-9 5284616
Known Target
Serine/threonine-protein kinase mTORP42345
Peptidyl-prolyl cis-trans isomerase FKBP1AP62942
Fibroblast growth factor 2P09038
Structure
...
Introduction
Rapamycin was used as a kind of original antifungal antibiotic, which is produced by Streptomyces hygroscopicus. Now it has been used in the prevention of transplant rejection because of its immunosuppressive effect. It also exhibits activity against several transplantable tumors and slightly activity to inactive against leukemias. The immunosuppressive effect of Rapamycin is exerted by inhibiting the activation and proliferation of T cells. Rapamycin binds to FK-binding protein 12 (FKBP12) and forms the rapamycin-FKBP12 complex, which regulates an enzyme that plays an important role in the progression of the cell cycle. Rapamycin was confirm to be the inhibitor of mTOR.

SN38

Cas.no PubChem ID
86639-52-3 104842
Known Target
DNA topoisomerase 1P11387
Structure
...
Introduction
SN-38 (7-ethyl-10-hydroxycamptothecin) is the active metabolite of Irinotecan (CPT-11). SN-38 has been found to be 200–2000 times more cytotoxic than CPT-11, but has not been used as an anticancer drug due to its poor solubility in pharmaceutically acceptable solvents and low affinity to lipid membranes.

Reference

  • [1] A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Yashiro, M., et al. (2013).Br J Cancer.109(10):2619-28.
    24129235. [ 24129235 ]

Back to top